Togni P, Sessa C, Varini M, Cavalli F
Schweiz Med Wochenschr. 1982 Jun 26;112(26):930-3.
Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto). Seven cases were previously untreated. A partial remission was observed only in one patient (6%, confidence limits to 95%: 1-17%). Marked gastrointestinal and hematologic toxicity was registered. Based on this experience the authors are unable to confirm other pilot studies claiming major antitumor activity for MOF-Strepto in the treatment of advanced colo-rectal cancer.
16例晚期结直肠癌患者接受了甲环亚硝脲、长春新碱、5-氟尿嘧啶和链脲佐菌素联合治疗（MOF-链脲佐菌素方案）。7例患者此前未接受过治疗。仅1例患者出现部分缓解（6%，95%置信区间：1%-17%）。出现了明显的胃肠道和血液学毒性。基于这一经验，作者无法证实其他初步研究中声称的MOF-链脲佐菌素方案在晚期结直肠癌治疗中具有主要抗肿瘤活性的说法。
